New drugs that exceed all expectations and open up new horizons in diabetes... and beyond

Later, the strategy focused on complications has emerged, where the new drugs (GLP-1 receptor agonists such as semaglutide, and SGLT-2 inhibitors) have been able to reduce the risk of cardiovascular and renal morbidity and mortality. However, as Dr. Juan José Gorgojo Martínez, head of the Endocrinology and Nutrition Service at the Hospital Universitario Fundación Alcorcón (Madrid), points out, “there is one more step: adopting the adipocentric s…